SCHEMBL2126963

SCHEMBL2126963

COc1c(C=Cc2ccc(NS(C)(=O)=O)cn2)cc(-c2ccc[nH]c2=O)cc1C1(C(F)F)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.54
▸ PIP4K2A P48426 6/20 0.34
▸ PIP4K2B P78356 6/20 0.34
▸ PIP4K2C Q8TBX8 1/20 0.33
▸ PDPK1 O15530 1/20 0.33
▸ TEAD2 Q15562 1/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ PIK3CB P42338 1/20 0.33
▸ PIK3CG P48736 1/20 0.33
▸ ACVR1 Q04771 3/20 0.32
▸ FYN P06241 2/20 0.32
▸ TGFBR1 P36897 1/20 0.32
▸ ABL1 P00519 1/20 0.31
▸ BRD4 O60885 2/20 0.31
▸ RIPK2 O43353 2/20 0.31
▸ NOD2 Q9HC29 2/20 0.31
▸ ALOX5AP P20292 1/20 0.31
▸ FEN1 P39748 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542473 1.00 CYP3A4 (0.54) CYP3A4PIP4K2APIP4K2BPIP4K2CPDPK1
SCHEMBL1542176 0.89 CYP3A4 (0.68) CYP3A4PIP4K2APIP4K2BPIP4K2CPDPK1
SCHEMBL2128628 0.89 CYP3A4 (0.68) CYP3A4PIP4K2APIP4K2BPIP4K2CPDPK1
SCHEMBL2127754 0.82 CYP3A4 (0.78) CYP3A4PIP4K2APIP4K2BPIP4K2CPDPK1
SCHEMBL1543171 0.82 CYP3A4 (0.78) CYP3A4PIP4K2APIP4K2BPIP4K2CPDPK1
SCHEMBL2127112 0.78 CYP3A4 (0.71) CYP3A4PIP4K2APIP4K2BPIP4K2CPDPK1
SCHEMBL1542961 0.78 CYP3A4 (0.71) CYP3A4PIP4K2APIP4K2BPIP4K2CPDPK1
SCHEMBL2745325 0.78 CYP3A4 (0.49) CYP3A4PIP4K2APIP4K2BPIP4K2CTEAD2
SCHEMBL2745328 0.78 CYP3A4 (0.49) CYP3A4PIP4K2APIP4K2BPIP4K2CTEAD2
SCHEMBL1542956 0.77 CYP3A4 (0.52) CYP3A4PIP4K2APIP4K2BPIP4K2CABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 — — EP claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 — — US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 — — US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 — — EP disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885PIP4K2A 2030/4885PIP4K2B 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback